Leerink Partnrs Has Negative Outlook for ASND Q2 Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities researchers at Leerink Partnrs cut their Q2 2025 EPS estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Wednesday, July 23rd. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($1.75) per share for the quarter, down from their prior forecast of ($1.50). The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.34) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S's Q3 2025 earnings at ($1.56) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($6.52) EPS and FY2026 earnings at ($1.60) EPS.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million.

Several other equities analysts have also weighed in on ASND. Citigroup increased their price target on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research report on Friday, July 11th. Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Oppenheimer reaffirmed an "outperform" rating and issued a $224.00 target price (up from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Finally, Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 target price on the stock. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND traded down $0.84 during trading on Friday, hitting $167.47. The stock had a trading volume of 421,932 shares, compared to its average volume of 412,063. The company has a market capitalization of $10.24 billion, a PE ratio of -26.67 and a beta of 0.38. The firm has a fifty day moving average of $170.63 and a two-hundred day moving average of $155.66. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently modified their holdings of ASND. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S in the 4th quarter worth about $28,000. Compagnie Lombard Odier SCmA bought a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $39,000. Brooklyn Investment Group boosted its stake in Ascendis Pharma A/S by 332.9% in the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares during the period. Quarry LP purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $96,000. Finally, Tower Research Capital LLC TRC raised its holdings in Ascendis Pharma A/S by 195.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after buying an additional 664 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.